PhaMix

PhaMix is a biotechnology company developing a proprietary drug delivery platform based on the science of liquid-liquid phase separation (LLPS). The company's core technology, the PhaMix platform, creates complex coacervates or protein condensates that stabilize biologics such as proteins, peptides, and nucleic acids, protecting them from degradation and enabling controlled, sustained release. By mimicking the natural formation of membraneless organelles, PhaMix aims to overcome significant barriers in the delivery of sensitive large-molecule drugs. The company is currently advancing pre-clinical programs in metabolic diseases, specifically focusing on oral and long-acting insulin delivery, as well as regenerative medicine applications like wound healing. PhaMix is a spin-out from the University of Illinois Chicago and is leveraging its platform to improve the therapeutic profile of various biologics.